Early Phase 1
N=9
Liver Positron Emission Tomography (PET) Study of Non Alcoholic Fatty Liver Disease
Fatty Liver
Bottom Line
View on ClinicalTrials.gov: NCT00949403 ↗Enrolled (actual)
9
Serious AEs
0.0%
Results posted
Jun 2020
Primary outcome: Primary: Hepatic Fatty Acid Oxidation
Study Design & Population
- Study type
- Interventional
- Phase
- Early Phase 1
- Interventions
- Radio pharmaceuticals C-11 Acetate, and C-11 Palmitate (Drug)
- Age
- Adult · 18+ yrs
- Sex
- Female
- Sponsor
- Washington University School of Medicine
- Primary completion
- Jan 2011
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Hepatic Fatty Acid Oxidation |
— | — |
Summary
The purpose of this study is to evaluate how the liver receives and uses fats for energy. This will help the investigators further understand the physical and chemical processes responsible for Non-Alcoholic Fatty Liver Disease (NAFLD) in overweight females with or without NAFLD who are scheduled to undergo gastric bypass surgery.
Eligibility Criteria
Inclusion Criteria
- Obese females with a BMI of greater then or equal to 45.
- Age range between 18-45 years.
- Patients undergoing bariatric surgery at Barnes-Jewish Hospital-St.Louis,MO.
Exclusion Criteria
- Any prior history or evidence of liver disease other than Non-Alcoholic Fatty liver Disease, severe hypertriglyceridemia and diabetes mellitis.
- Consumed greater then or equal to 20 grams of alcohol per day.
- Taking medications that are known to cause hepatic steatosis & liver damage.
Data sourced from ClinicalTrials.gov (NCT00949403). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.